Evidence map›Paper›PMID 42429995›Full record

ArticleMolecular biology reports2026

A potent small-chemical MBD2 inhibitor, KCC-07, induces selective cytotoxicity in hepatocellular and prostate cancer cells.

Kasım Kağan Koca, Zeyneb Nur Akçay, Gizem Kugu, Fatma Özdemir, Olcay Arman Gürer, Merve Tuzlakoğlu Öztürk, Uygar Halis Tazebay, Ali Iftikhar, Shafaat Ahmed Rabbani, Zihni Onur Çalışkaner

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kasım Kağan KocaMolecular Biology and Genetics, Gebze Technical University, Kocaeli, 41400, Türkiye.ORCID http://orcid.org/0009-0008-2277-6041
Zeyneb Nur AkçayMolecular Biology and Genetics, Biruni University, Istanbul, 34015, Türkiye.ORCID http://orcid.org/0009-0008-3429-7996
Gizem KuguMolecular Biology and Genetics, Gebze Technical University, Kocaeli, 41400, Türkiye.ORCID http://orcid.org/0000-0003-0404-3991
Fatma ÖzdemirMolecular Biology and Genetics, Biruni University, Istanbul, 34015, Türkiye.ORCID http://orcid.org/0009-0005-5895-1014
Olcay Arman GürerMolecular Biology and Genetics, Biruni University, Istanbul, 34015, Türkiye.ORCID http://orcid.org/0009-0008-9376-0768
Merve Tuzlakoğlu ÖztürkMolecular Biology and Genetics, Gebze Technical University, Kocaeli, 41400, Türkiye.ORCID http://orcid.org/0000-0001-5983-2854
Uygar Halis TazebayMolecular Biology and Genetics, Gebze Technical University, Kocaeli, 41400, Türkiye.ORCID http://orcid.org/0000-0003-1999-8213
Ali IftikharDepartment of Human Genetics, McGill University, Montréal, QC, H4A3J1, Canada.ORCID http://orcid.org/0000-0001-5828-0488
Shafaat Ahmed RabbaniDepartment of Human Genetics, McGill University, Montréal, QC, H4A3J1, Canada.ORCID http://orcid.org/0000-0001-5594-3899
Zihni Onur ÇalışkanerMolecular Biology and Genetics, Biruni University, Istanbul, 34015, Türkiye. zcaliskaner@biruni.edu.tr.ORCID http://orcid.org/0000-0003-1385-1739

Funding

Türkiye Sağlık Enstitüleri Başkanlığı 2022-B-02-22387
6 · The paper itself

Abstract

backgroundMethyl-CpG-binding domain protein 2 (MBD2) is a key epigenetic regulator implicated in tumorigenesis by repressing tumor suppressor genes by recognizing DNA methylation marks and recruiting specific histone-modifying enzymes and chromatin remodeling complexes. Although KCC-07 has been identified as a potent selective MBD2 inhibitor, its cytotoxic effects on various cancer cells remain largely unexplored. In the current study, we have examined the anti-proliferative and cytotoxic activities of KCC-07 on breast cancer (MCF-7), prostate cancer (PC-3), hepatocellular carcinoma (Huh-7), and osteosarcoma (U2-OS) cell lines, along with human skin fibroblasts (HFF-1) as a non-malignant control. METHODS AND

resultsTreatment of these cells with KCC-07 induced dose- and time-dependent cytotoxicity, notably reducing viability in Huh-7 and PC-3 cells. Flow cytometry analyses revealed that KCC-07 primarily triggered necrosis in Huh-7 and apoptosis in PC-3 cells. Furthermore, KCC-07 substantially downregulated MBD2-associated oncogenic targets such as WNT1, CCND1, and ERK1/2 in Huh-7 and PC-3 cells without altering MBD2 transcription.

conclusionThese findings suggest that KCC-07 elicited a considerable cytotoxicity on cancer cells, likely modulating the expression of MBD2-related genes, highlighting its potential as a candidate for cancer therapy.

Indexed as

Carcinoma, HepatocellularDNA-Binding ProteinsLiver NeoplasmsProstatic NeoplasmsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalDNA MethylationGene Expression Regulation, NeoplasticHumansMaleMCF-7 CellsPC-3 CellsAntineoplastic AgentsDNA-Binding ProteinsMBD2 protein, humanCancer cell lineDNA methylationEpigeneticsMBD2 inhibitorOncogene

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.